Using continuous glucose monitoring to identify diabetes risk in cystic fibrosis patients
Identification of Dysglycemia With Continuous Glucose Monitoring: A Prospective Study to Assess the Relationship With Clinical Evolution in Cystic Fibrosis
This study is testing if continuous glucose monitoring can help find out which cystic fibrosis patients are at risk for diabetes by tracking their health over five years.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 121 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Institut de Recherches Cliniques de Montreal Academic / other |
| Locations | 4 sites (Montreal, Quebec and 3 other locations) |
| Trial ID | NCT05099939 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the predictive value of continuous glucose monitoring (CGM) in assessing the clinical evolution of adult patients with cystic fibrosis (CF). Over a period of five years, the study will track the clinical condition of participants, including lung function and nutritional status, while collecting detailed glycemic profiles through CGM at three different visits. The primary goal is to identify CGM variables that correlate with a decline in pulmonary function and other clinical markers. This approach seeks to provide a less invasive and more effective alternative to the standard oral glucose tolerance test for screening diabetes in CF patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older diagnosed with cystic fibrosis.
Not a fit: Patients who are currently receiving pharmaceutical treatment for diabetes or have had a lung or liver transplant may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved early detection and management of diabetes in cystic fibrosis patients, potentially reducing morbidity and mortality associated with the condition.
How similar studies have performed: While the use of continuous glucose monitoring in other populations has shown promise, this specific application in cystic fibrosis is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Have cystic fibrosis * Be 18 years of age or older * Have given clear and informed consent Exclusion Criteria: * Receive pharmaceutical treatment for diabetes * Have had a lung or liver transplant * Participate in a randomized controlled trial for more than 3 months in parallel with this study * Currently pregnant * Patients under legal protection (for centers in France)
Where this trial is running
Montreal, Quebec and 3 other locations
- Institut de recherches cliniques de Montréal — Montreal, Quebec, Canada (Recruiting)
- Centre Hospitalier de l'Université de Montréal — Montreal, Quebec, Canada (Not_yet_recruiting)
- Hospices Civils de Lyon — Lyon, France (Not_yet_recruiting)
- CHU de Strasbourg — Strasbourg, France (Not_yet_recruiting)
Study contacts
- Principal investigator: Rémi Rabasa-Lhoret — Institut de recherches cliniques de Montréal
- Study coordinator: Katherine Desjardins
- Email: katherine.desjardins@ircm.qc.ca
- Phone: 5149875666
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.